NYSE:NGMNGM Biopharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NGM Biopharmaceuticals Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.82 -0.32 (-1.67 %) (As of 08/11/2020 04:00 PM ET) Add Compare Share Today's Range$18.74Now: $18.82▼$19.3550-Day Range$17.91MA: $19.38▼$22.9152-Week Range$8.81Now: $18.82▼$23.95Volume138,726 shsAverage Volume314,748 shsMarket Capitalization$1.28 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 4.6 Analyst's Opinion Consensus RatingNGM Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.50, NGM Biopharmaceuticals has a potential upside of 67.4% from its current price of $18.82.Amount of Analyst CoverageNGM Biopharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.3 Community Rank Outperform VotesNGM Biopharmaceuticals has received 54 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNGM Biopharmaceuticals has received 28 “underperform” votes. (Add your “underperform” vote.)Community SentimentNGM Biopharmaceuticals has received 65.85% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NGM Biopharmaceuticals and other stocks. Vote “Outperform” if you believe NGM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NGM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNGM Biopharmaceuticals does not currently pay a dividend.Dividend GrowthNGM Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NGM Biopharmaceuticals insiders have bought 25.75% more of their company's stock than they have sold. Specifically, they have bought $1,318,286.00 in company stock and sold $1,048,364.00 in company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 4.6Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.97 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSE:NGM Previous Symbol CUSIPN/A CIKN/A Webwww.ngmbio.com Phone650-243-5555Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees186 Outstanding Shares68,142,000Market Cap$1.28 billion Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable $18.82 -0.32 (-1.67 %) (As of 08/11/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NGM News and Ratings via Email Sign-up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter. NGM Biopharmaceuticals (NYSE:NGM) Frequently Asked Questions How has NGM Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? NGM Biopharmaceuticals' stock was trading at $15.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NGM shares have increased by 22.6% and is now trading at $18.82. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of NGM Biopharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NGM Biopharmaceuticals. When is NGM Biopharmaceuticals' next earnings date? NGM Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for NGM Biopharmaceuticals. How were NGM Biopharmaceuticals' earnings last quarter? NGM Biopharmaceuticals (NYSE:NGM) issued its earnings results on Wednesday, May, 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.01. The business earned $24.36 million during the quarter, compared to analysts' expectations of $19.92 million. View NGM Biopharmaceuticals' earnings history. What price target have analysts set for NGM? 8 Wall Street analysts have issued twelve-month target prices for NGM Biopharmaceuticals' stock. Their forecasts range from $28.00 to $40.00. On average, they anticipate NGM Biopharmaceuticals' share price to reach $31.50 in the next year. This suggests a possible upside of 67.4% from the stock's current price. View analysts' price targets for NGM Biopharmaceuticals. What are Wall Street analysts saying about NGM Biopharmaceuticals stock? Here are some recent quotes from research analysts about NGM Biopharmaceuticals stock: 1. According to Zacks Investment Research, "NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc. is based in San Francisco, California. " (7/22/2020) 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $26 target price after NGM reported its 2Q19 financials and business update. We remain positively biased ahead of NGM282’s (aldafermin) Phase 2 cohort 4 interim data expected in 4Q19 (non-invasive biomarkers), but more importantly, aldafermin’s top line results in early 2020 where we believe it has the potential to demonstrate a histological fibrosis benefit in NASH patients in as little as 24 weeks of treatment. The latter remains the key catalyst for the stock, in our view. In the press release, NGM indicated it had completed enrollment for cohort 4 and management also highlighted pipeline progress for some of its earlier stage programs including for NGM621, which is being developed for geographic atrophy, and NGM120 for CACS." (8/14/2019) Has NGM Biopharmaceuticals been receiving favorable news coverage? Media coverage about NGM stock has trended neutral on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. NGM Biopharmaceuticals earned a news impact score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about NGM Biopharmaceuticals. Who are some of NGM Biopharmaceuticals' key competitors? Some companies that are related to NGM Biopharmaceuticals include MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR), MorphoSys (MOR), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), Repare Therapeutics (BLI), MorphoSys (MOR), BTG (BTG), Cronos Group (CRON), Abcam (ABC), Genus (GNS), Kodiak Sciences (KOD), Viela Bio (VIE), Mesoblast (MSB), Polynovo (PNV) and Concordia International (CXR). View all competitors. What other stocks do shareholders of NGM Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NGM Biopharmaceuticals investors own include Viking Therapeutics (VKTX), Opko Health (OPK), Alibaba Group (BABA), AbbVie (ABBV), Johnson & Johnson (JNJ), Bristol-Myers Squibb (BMY), Pfizer (PFE), AT&T (T), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX). Who are NGM Biopharmaceuticals' key executives? NGM Biopharmaceuticals' management team includes the following people: Mr. William J. Rieflin J.D., Exec. Chairman of Directors (Age 60)Dr. David J. Woodhouse, CEO, Acting CFO & Director (Age 49, Pay $615.75k)Dr. Jin-Long Chen, Founder, Chief Scientific Officer & Director (Age 57, Pay $625.75k)Dr. Aetna Wun Trombley, Consultant (Age 40, Pay $550.75k)Ms. Valerie L. Pierce, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 57) When did NGM Biopharmaceuticals IPO? (NGM) raised $100 million in an initial public offering on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO. What is NGM Biopharmaceuticals' stock symbol? NGM Biopharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGM." Who are NGM Biopharmaceuticals' major shareholders? NGM Biopharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.34%), SG Americas Securities LLC (0.12%), RMB Capital Management LLC (0.08%), Russell Investments Group Ltd. (0.06%), Principal Financial Group Inc. (0.05%) and Virtus ETF Advisers LLC (0.02%). Company insiders that own NGM Biopharmaceuticals stock include David V Goeddel, Group L P Column, Hsiao D Lieu, Jin-Long Chen, Merck & Co, Inc, Peter Svennilson and Suzanne Sawochka Hooper. View institutional ownership trends for NGM Biopharmaceuticals. Which institutional investors are selling NGM Biopharmaceuticals stock? NGM stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., and UBS Group AG. Company insiders that have sold NGM Biopharmaceuticals company stock in the last year include Group L P Column, Hsiao D Lieu, and Jin-Long Chen. View insider buying and selling activity for NGM Biopharmaceuticals. Which institutional investors are buying NGM Biopharmaceuticals stock? NGM stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, RMB Capital Management LLC, Principal Financial Group Inc., Virtus ETF Advisers LLC, Raymond James Financial Services Advisors Inc., Russell Investments Group Ltd., ProShare Advisors LLC, and Strs Ohio. Company insiders that have bought NGM Biopharmaceuticals stock in the last two years include David V Goeddel, Group L P Column, Merck & Co, Inc, Peter Svennilson, and Suzanne Sawochka Hooper. View insider buying and selling activity for NGM Biopharmaceuticals. How do I buy shares of NGM Biopharmaceuticals? Shares of NGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is NGM Biopharmaceuticals' stock price today? One share of NGM stock can currently be purchased for approximately $18.82. How big of a company is NGM Biopharmaceuticals? NGM Biopharmaceuticals has a market capitalization of $1.28 billion. NGM Biopharmaceuticals employs 186 workers across the globe. What is NGM Biopharmaceuticals' official website? The official website for NGM Biopharmaceuticals is www.ngmbio.com. How can I contact NGM Biopharmaceuticals? The company can be reached via phone at 650-243-5555. This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
